T
Todd E. DeFor
Researcher at University of Minnesota
Publications - 297
Citations - 19625
Todd E. DeFor is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 64, co-authored 288 publications receiving 17856 citations. Previous affiliations of Todd E. DeFor include City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
Natural history of pulmonary complications in children after bone marrow transplantation
Mark Eikenberry,Hana Bartakova,Todd E. DeFor,Imad Y. Haddad,Norma K.C. Ramsay,Bruce R. Blazar,Carlos Milla,David N. Cornfield +7 more
TL;DR: Although pathogen identification does not confer a survival advantage, rigorous, prospective screening may allow for earlier identification of pathogens and thereby provide a benefit to this uniquely vulnerable population.
Journal ArticleDOI
Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients
Angela R. Smith,Navneet S. Majhail,Margaret L. MacMillan,Todd E. DeFor,Sonata Jodele,Leslie Lehmann,Robert A. Krance,Stella M. Davies +7 more
TL;DR: The results indicate that the HCT-CI score predicts NRM and OS in pediatric patients undergoing HCT and is a useful tool to assess risk, guide counseling in the pretransplantation setting, and devise innovative therapies for the highest risk groups.
Journal ArticleDOI
Response to thalidomide therapy in refractory chronic graft-versus-host disease.
Paul Browne,Daniel J. Weisdorf,Todd E. DeFor,Wesley J. Miller,Stella M. Davies,Alexandra H. Filipovich,P B McGlave,N. K. C. Ramsay,John E. Wagner,Helen Enright +9 more
TL;DR: It is concluded that thalidomide is a useful and well-tolerated therapy for patients with previously treated refractory chronic GVHD, including those with progressive onset of chronic GvHD, recipients of unrelated donor marrow, and children.
Journal ArticleDOI
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse
TL;DR: GVHD and its accompanying graft-versus-leukemia effect may better protect BM sites, but patients with EM relapse have better responses to combined therapy and improved survival compared with those with BM relapse.
Journal ArticleDOI
Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia.
Stella M. Davies,John E. Wagner,Todd E. DeFor,Bruce R. Blazar,Emmanuel Katsanis,John H. Kersey,Paul J. Orchard,P B McGlave,Daniel J. Weisdorf,Norma K.C. Ramsay +9 more
TL;DR: Early referral for consideration of unrelated donor BMT for young patients with MDS, and patients with SAA without response to immunosuppression are recommended.